Key information

🔎 Fund Overview

Ikena Oncology, Inc. is a targeted oncology company. The Company develops precision medicines tailored to biomarker-defined patient groups with specific unmet needs. The Company approach in each of its programs is to target both cancer-driving targets and mechanisms of resistance to other targeted therapies. The Company’s advanced targeted oncology program, IK-930, is a paralog-selective inhibitor of the transcriptional enhanced associate domain (TEAD). The TEAD transcription factors execute the ultimate step in the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted and chemo therapies. The Company’s first program in the RAS pathways, IK-595, is designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. In addition, it is also developing IK-175, an aryl hydrocarbon receptor (AHR) antagonist in collaboration with Bristol Myers Squibb.